Inflammasomes: Molecular Regulation and Implications for Metabolic and Cognitive Diseases

The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters

Citation

Published Version
doi:10.14348/molcells.2014.0104

Citable link
http://nrs.harvard.edu/urn-3:HUL.InstRepos:12717485

Terms of Use
This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Inflammasomes: Molecular Regulation and Implications for Metabolic and Cognitive Diseases

Alexander J.S. Choi¹, and Stefan W. Ryter²,³,*

Inflammasomes are specialized signaling platforms critical for the regulation of innate immune and inflammatory responses. Various NLR family members (i.e., NLRP1, NLRP3, and IPAF) as well as the PYHIN family member AIM2 can form inflammasome complexes. These multi-protein complexes activate inflammatory caspases (i.e., caspase-1) which in turn catalyze the maturation of select pro-inflammatory cytokines, including interleukin (IL)-1β and IL-18. Activation of the NLRP3 inflammasome typically requires two initiating signals. Toll-like receptor (TLR) and NOD-like receptor (NLR) agonists activate the transcription of pro-inflammatory cytokine genes through an NF-κB-dependent priming signal. Following exposure to extracellular ATP, stimulation of the P2X purinoreceptor-7 (P2X7R), which results in K⁺ efflux, is required as a second signal for NLRP3 inflammasome formation. Alternative models for NLRP3 activation involve lysosomal destabilization and phagocytic NADPH oxidase and/or mitochondria-dependent reactive oxygen species (ROS) production. In this review we examine regulatory mechanisms that activate the NLRP3 inflammasome pathway. Furthermore, we discuss the potential roles of NLRP3 in metabolic and cognitive diseases, including obesity, type 2 diabetes mellitus, Alzheimer’s disease, and major depressive disorder. Novel therapeutics involving inflammasome activation may result in possible clinical applications in the near future.

INTRODUCTION

Inflammation involves a tightly regulated process, characterized by two complementary subsystems: the innate immune system and the subsequent, highly adaptive immune system. The innate immune system is activated by invasive pathogens that target pattern recognition receptors (PRRs), such as membrane-bound Toll-like receptors (TLRs) and cytosolic NOD-like receptors (NLRS). While TLRs detect both extracellular and intracellular stimuli, NLRS respond to cytosolic agonists. The NLR family contains various proteins that act as scaffolds that can oligomerize into larger protein complexes, thereby inducing the formation of a molecular platform called the inflammasome. These multi-protein complexes contribute to the activation of inflammatory caspases (i.e., caspase-1) that result in the proteolytic processing and secretion of cytokines, including interleukin (IL)-1β and IL-18 (Martinon et al., 2009). Therefore, inflammasomes, which include members of the NLR family (i.e., NLRP1, NLRP3, and IPAF) as well as the PYHIN family member AIM2, represent critical mediators of cellular stress in the innate and adaptive immune systems (Fig. 1). This review will discuss the importance of inflammasome pathways, specifically, that of the most fully characterized NLRP3 inflammasome, in metabolic and cognitive diseases, including obesity, type 2 diabetes mellitus, Alzheimer’s disease, and major depressive disorder (Fig. 2).

STRUCTURAL ORGANIZATION

The NLR family

The NLR protein family consists of the NLRPs (NLRP1-14, or NALP1-14) and the ICE-protease-activating factor (IPAF) subfamily. Most NLRs contain the nucleotide-binding and oligomerization (NACHT) domain, which enables activation of the pro-inflammatory cytokine signaling pathways via ATP-dependent oligomerization. The NACHT domain is usually surrounded by C-terminal leucine-rich repeats (LRRs) and an N-terminal caspase and recruitment domain (CARD) or pyrin domain (PYD) (Schroder and Tschopp, 2010). The PYD domain of NLRPs recruits the adapter apoptosis-associated speck-like protein containing a caspase recruitment domain (ASC), which contains an N-terminal PYD and a C-terminal CARD. Furthermore, the CARD domain of ASC represents an essential component for inflammasome formation via caspase-1 binding (Mariathasan et al., 2004; Martinon et al., 2002).

The NLRP1, NLRP3, and IPAF inflammasomes harbor structural distinctions that enable caspase-1 recruiting. The NLRP1 inflammasome contains a C-terminal CARD that recruits pro-caspase-1 (Faustin et al., 2007) or pro-caspase-5 (Martinon et al., 2002). As a result, NLRP1 does not require recruitment of
Fig. 2. NLRP3 has been implicated in pro-pathogenic responses related to several human diseases, including neurocognitive disorders and metabolic disorders, although the mechanisms remain incompletely clear. Neurons and astrocytes may represent targets of NLRP3-dependent inflammatory processes, leading to the promotion of neurocognitive disorders. Adipocyte differentiation and growth have been linked to NLRP3-dependent processes in obesity. Hepatic insulin resistance and inflammation may also be mediated in part by NLRP3-dependent inflammation.

ASC to interact directly with caspase-1. However, ASC has been shown to enhance NLRP1-mediated caspase-1 activation in vitro (Faustin et al., 2007). In contrast to most proteins of the NLR family, the NLRP3 protein lacks the typical CARD domain. The PYD domain of NLRP3 interacts with ASC, whose CARD domain recruits the CARD of pro-caspase-1 (Schroder and Tschopp, 2010). Finally, the IPAF protein lacks a PYD domain (Schroder and Tschopp, 2010), but contains a CARD domain that interacts directly with pro-caspase-1 without the need of ASC (Poyet et al., 2001). Therefore, IPAF may interact with a PYD-containing protein (i.e., NLRPs) for appropriate inflammatory responses to invasive pathogens (Schroder and Tschopp, 2010).

AIM2 inflammasome
The pyrin and HIN domain-containing protein (PYHIN) family member absent in melanoma 2 (AIM2 inflammasome) represents the first non-NLR family member identified that can form an inflammasome complex (Ludlow et al., 2005; Schroder and Tschopp 2010). While most inflammasomes in the NLR family depend on a central NACHT domain for oligomerization, AIM2 uses multiple binding sites for cytosolic DNA via its C-terminal HIN200 domain. Similar to NLRP3, AIM2 contains a PYD domain that interacts with ASC via homotypic PYD-PYD interactions, which allows the CARD domain within ASC to regulate nuclear factor kappa B (NF-κB) and caspase-1 production (Hornung et al., 2009). As a result, AIM2-mediated caspase-1 activation induces pro-inflammatory cytokine secretion (i.e., IL-1β, IL-18) (Schroder and Tschopp, 2010).

NLRP3 INFLAMMASOME ACTIVATION AND REGULATION

TLR-dependence
TLRs are critical receptors that regulate inflammasome activity and pro-IL-1β production. TLR agonists, such as lipopolysaccharide (LPS), induce pro-IL-1β secretion via the NF-κB transcription factor and IL-1β promoter activation (Hiscott et al., 1993; Schroder and Tschopp, 2010). Prior to caspase-1-mediated pro-
teolytic cleavage of IL-1β. TLR agonists facilitate the NLRP3 inflammasome pathway through an NF-κB-dependent priming signal, which may represent a rate-limiting component of inflammasome complex formation (Bauerfeind et al., 2009; Guarda et al., 2011). Other studies have suggested the importance of TLR4 in the inflammasome pathway. For example, CD14, a phagocyte-expressed PRR known to interact with TLR4, increased TLR4-mediated inflammatory response to LPS (Fujihara et al., 2003) and monosodium urate (MSU) (Scott et al., 2006). Furthermore, LPS failed to induce NLRP3 or pro-IL-1β activation in cells lacking a functional TLR4 receptor (Bauerfeind et al., 2009). Franchi et al. (2009) demonstrated that the presence of ATP was required for TLR4-dependent caspase-1 activation following exposure to LPS.

**ATP-dependence**

Extracellular ATP activates the P2X purinoreceptor 7 (P2X7) via the pannexin-1 hemichannel, which was proposed to permit the bacterial ligand to enter the cytosol to induce caspase-1 expression (Kanneganti et al., 2007). P2X7-dependent pro-caspase-1 activation and IL-1β secretion have been found to facilitate NF-κB activation via a TNF-α-dependent pathway, thereby suggesting an important role of P2X-R in NLRP3 inflammasome complex formation (Solini et al., 2013; Wen et al., 2011). ATP-mediated P2X7-R stimulation has also been shown to induce a K+ efflux, which indicates that reduced intracellular K+ concentration triggers the NLRP3 inflammasome pathway (Pétrit et al., 2007). Furthermore, suppressed NLRP3 activity has been reported to result from treatment with the ATP-sensitive K+ channel inhibitor, glibenclamide, and the chemical ROS scavenger, (2R,4R)-4-aminopyrrolidine-2,4-dicarboxylate (Dostert et al., 2008). For example, NADPH oxidase-induced reactive oxygen species (ROS) production (Altmann et al., 2008). P2X7-R has been shown to mediate NADPH oxidase-dependent oxidative stress both in vivo (Chatterjee et al., 2012) and in vitro (Korcok et al., 2004; Liu et al., 2011), thereby indicating a critical role for P2X-R in activation of the NLRP3 inflammasome via ROS signaling.

Furthermore, recent studies suggest that treatment of macrophages with the mitochondria-targeted antioxidant Mito-TEMPO, a TEMPO derivative that targets mitochondrial ROS (Trnka et al., 2009), reduced secretion of both IL-1β and IL-18. Mito-TEMPO inhibited subsequent caspase-1 activation and mitochondrial DNA (mtDNA) translocation to the cytosol in response to LPS and ATP (Nakahira et al., 2011). However, Mito-TEMPO did not inhibit IL-1β secretion following exposure to treatment with LPS and MSU, indicating that this pathway is independent of mitochondrial ROS (Nakahira et al., 2011). In conclusion, while ROS production represents a critical prerequisite to the NLRP3 inflammasome activation pathway, the source of ROS may vary with experimental models.

**NLRP3 inflammasome in metabolic disorders**

Recently, the prevalence of metabolic disorders, such as obesity, type 2 diabetes mellitus (T2DM), and atherosclerosis has risen tremendously (Davis et al., 2011). The World Health Organization (WHO) estimates that over 2.8 million adults above the age of 20 die each year worldwide due to being overweight (BMI ≥ 25 kg/m²) or suffering from obesity (BMI ≥ 30 kg/m²). In 2008, 10-14% of adults were clinically obese, in contrast to 5-6% of men and women in 1980 (Finucane et al., 2011; WHO, 2011). Furthermore, obesity increases the risk of diabetes, heart disease, stroke, hypertension, and depression (WHO, 2002). In 2006, diabetes alone accounted for 1.3 million deaths (WHO, 2011). In recent years, several studies have illustrated the chronic pro-inflammatory processes involved in the onset of metabolic disorders, including obesity and diabetes (Davis et al., 2011).

Obesity can stem from a variety of factors, such as genetics, aging, and unhealthy lifestyle habits (Skeldon et al., 2014). Adipose tissue in obese individuals releases more free fatty acids, hormones (i.e., leptin), pro-inflammatory cytokines (i.e., TNF-α, IL-1β), signaling proteins, and transcription factors that lead to insulin resistance (Shoelson et al., 2006; Wellen and Hotamisligil, 2005). Insulin resistance associated with dysfunctional insulin release from pancreatic islet β-cells impairs blood glucose tolerance, which typifies the development of T2DM (Kahn et al., 2006).

**Obesity**

Inflammation is associated with metabolic disorders, such as obesity. Recent studies have shown that the NLRP3 inflammasome may contribute to obesity. For example, weight loss due to calorie restriction or exercise in obese individuals with T2DM not only reduced NLRP3 expression and inflammation in adipose tissue and liver, but also improved insulin sensitivity (Vandanmagsar et al., 2011). In addition, mice deficient in NLRP3, ASC, and caspase-1 did not exhibit obesity-induced insulin resistance, which suggests that the NLRP3 inflammasome may act as a cellular regulator of insulin sensitivity (Vandanmagsar et al., 2011). However, since loss of NLRP3 function did not affect caspase-1 activation in the kidney of...
Type 2 diabetes mellitus (T2DM)

Type 2 diabetes mellitus (T2DM) is an auto-inflammatory disease induced by metabolic stressors, such as elevated levels of glucose and free fatty acids (FFAs) (Donath and Shoelson, 2011). Many studies have indicated a critical role of inflammatory processes in cases related to T2DM. For example, pro-inflammatory cytokines, TNF-α, IL-1β and IFN-γ, activate signaling pathways that result in pancreatic β-cell death and dysfunction (Eizirik et al., 2012; Feve et al., 2009; Mraz et al., 2011). As a result, elevated IL-1β levels and limited β-cell function are two primary predictors for the development of T2DM through inhibition of insulin signaling (Wang et al., 2014a). Additionally, recent studies have shown that inhibition of IL-1β production reduced T2DM prevalence in animal models (Emanuela et al., 2012; Mandrup-Poulsen et al., 2010). Furthermore, NLRP3-dependent IL-1β secretion during metabolic stress due to chronic hyperglycemia may contribute to the development of T2DM (Schröder et al., 2010). These findings suggest that IL-1β production via NLRP3 inflammasome activation is involved in the pathogenesis of T2DM.

The NLRP3 inflammasome has been shown to bind to thioredoxin interacting protein (TXNIP), which facilitates ROS-mediated NLRP3 activation via inhibition of thioredoxin (Skelton et al., 2014). A recent study has illustrated a potential role for TXNIP in innate immunity via formation of the NLRP3 inflammasome and release of IL-1β in diabetes and oxidative stress (Devi et al., 2012). Also, pancreatic β-cell death and insulin resistance in T2DM have been associated with IL-1β secretion mediated by the ROS-TXNIP axis, thereby enhancing NLRP3 activation (Zhou et al., 2010). This involvement of ROS-TXNIP in T2DM is consistent with the requirement for ROS in the NLRP3 inflammasome pathway (Wang et al., 2014a).

Therefore, the NLRP3 inflammasome may contribute to the pathogenesis of T2DM via the TXNIP protein (Wang et al., 2014a). However, the mechanisms that induce ROS generation in response to metabolic stress, such as chronic hyperglycemia, remain incompletely understood.

Targeting specific components of the inflammasome pathway may provide a plausible approach for treatment of T2DM. For example, glibenclamide, a drug widely used to treat T2DM, has been shown to inhibit formation of the glucose-induced TXNIP-NLRP3 inflammasome complex (Zhou et al., 2010). Palmitate, a saturated fatty acid found in plasma, triggers the secretion of IL-1β and IL-18 from macrophages via an NLRP3-dependent pathway (Wen et al., 2011). In addition, islet amyloid polypeptide (IAPP), a protein that forms amyloid deposits in the pancreas during T2DM, enhanced IL-1β secretion and NLRP3 activation in vitro (Masters et al., 2010). However, this same study reported that IL-1β release in response to IAPP depended on NLRP3, but not TXNIP (Masters et al., 2010). Therefore, TXNIP appears to represent an agonist-dependent protein within the NLRP3 inflammasome pathway.

NLRP3 inflammasome in cognitive diseases

Although neurocognitive diseases, such as Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, and major depressive disorder (MDD), are not often characterized as typical inflammatory diseases, recent research has indicated that activation of the innate immune system may contribute to their pathogenesis (Glass et al., 2010). PRRs, such as the TLR4 receptor, are highly expressed on immune cells (i.e., microglia and astrocytes) that induce inflammatory processes via cytokine secretion (Saito et al., 2009). Considering that TLR4 polymorphisms have been linked to several human age-related diseases (i.e., Alzheimer’s disease, atherosclerosis, and T2DM), such receptors may influence neurodegenerative diseases via inflammatory responses (Ballestri et al., 2009). In addition to PRRs, purinergic receptors (i.e., P2X7-R) are expressed on microglia and astrocytes. Furthermore, upregulation of this receptor has been reported in mouse models of Alzheimer’s disease (Parvathenani et al., 2003). Thus, PRRs and purinergic receptors on immune cells appear not only to serve as initial sensors of microbial pathogens, but they also likely induce inflammatory pathways associated with cognitive diseases, such as Alzheimer’s disease and MDD (Glass et al., 2010).

Alzheimer’s disease

Alzheimer’s disease is characterized by progressive dementia that stems from accumulation of amyloid-beta (Aβ) plaques in the cerebral, which leads to chronic inflammation and subsequent neuronal cell death (Leemans et al., 2011). During the 1980s, patients suffering from Alzheimer’s disease exhibited elevated levels of microglia, the primary phagocyte in the central nervous system (CNS) (Itagaki et al., 1989; McGeer et al., 1987). Since then, amyloid plaques have been shown to activate microglia, thereby inducing the neuronal abnormalities associated with Alzheimer’s disease (Meyer-Luehmann et al., 2008). However, it is still debated whether Aβ accumulation is the result of chronic inflammation in amyloid-effected tissue or other disease-related processes (Leemans et al., 2011).

Numerous studies have identified a critical role for IL-1β and the NLRP3 inflammasome in the pathogenesis of Alzheimer’s disease. For example, Halle et al. (2008) reported that Aβ phagocytosis induced IL-1β secretion via NLRP3-dependent activation of caspase-1, thereby suggesting involvement of the NLRP3 inflammasome in Alzheimer’s disease. Exposing LPS-
primed macrophages to fibrillar Aβ activated caspase-1 and triggered IL-1β release; this response was dependent on NLRP3 and involved both endosomal rupture and cathepsin B release (Halle et al., 2008). Furthermore, inhibition of cathepsin B has been shown to provide therapeutic benefit in a mouse model of Alzheimer’s disease (Hook et al., 2008). Considering the role of cathepsin B in caspase-1 activation, this finding provides further evidence for the involvement of the NLRP3 inflammasome pathway in Alzheimer’s disease.

A recent study reported upstream inflammatory processes in the context of Alzheimer’s disease in vivo (Heneka et al., 2013). NLRP3 or Casp1-/- mice crossed into APP/PS1 transgenic mice with mutations associated with Alzheimer’s disease (Jankowsky et al., 2001) exhibited reduced symptoms associated with this cognitive disease, including chronic Aβ secretion, neuronal inflammation, and cognitive impairment (Heneka et al., 2013). The same study demonstrated reduced release of caspase-1 and IL-1β in the brain and enhanced Aβ clearance, which suggests that NLRP3 functions in the pathogenesis of Alzheimer’s disease (Heneka et al., 2013). More importantly, these findings indicate that innate immune responses, specifically those related to inflammasome activation, contribute to neurocognitive disease onset and progression.

Major depressive disorder (MDD)

Major depressive disorder (MDD), also known as depression, is a severe neuropsychiatric illness that involves significant changes in mood, self-esteem, circadian rhythms, eating, and cognition (Iwata et al., 2013). While MDD affects at least 10% of the population in the United States (Kessler et al., 2003), its biosynthetic pathway remains unresolved. Previous studies suggest that environmental stimuli can lead to inflammatory processes (i.e., cytokine secretion and NLRP3 inflammasome activation), neurological changes, and MDD onset. For example, inflammatory cytokines (i.e., IL-1β, IL-6, and TNF-α) have been shown to play an important role in major depression (Dowlati et al., 2010; Maes et al., 1993). Moreover, Iwata and colleagues have proposed that IL-1β secretion represents the initial step of the pro-inflammatory response to psychological stress (Iwata et al., 2013). In agreement with this proposal, IL-1β release has been implicated to facilitate depressive behaviors (i.e., anhedonia) via the NF-κB pathway following both acute (i.e., foot-shock or immobilization) and chronic unpredictable stress (Koo and Duman, 2008).

Recent literature has examined a close relationship between depression and the NLRP3 inflammasome. For example, patients diagnosed with MDD exhibit increased levels of cytokines, IL-1β and IL-18, as well as NLRP3 inflammasome in peripheral blood mononuclear cells (PBMCs) (Alcocer-Gómez and Cordero, 2013). Also, IL-1β and NLRP3 inflammasome mRNA expression levels showed a significant increase in mouse brain following LPS-induced depression, which indicates that IL-1β and NLRP3 act as inflammatory mediators for psychological stress and depression (Zhang et al., 2013). In contrast to recent studies that suggest a critical role for mitochondrial rupture during NLRP3 activation (Latz et al., 2013; Nakahira et al., 2011), the inflammasome pathway in MDD patients does not depend on mitochondrial dysfunction (Alcocer-Gómez and Cordero, 2013). As a result, the mechanisms underlying the effect of psychological stress on inflammasome formation are still debated.

Of clinical relevance, several recent studies indicate that antidepressant medications regulate inflammasome activation. For example, amitriptyline, a common tricyclic antidepressant, has been shown to inhibit IL-1β and IL-18 production, as well as NLRP3 and caspase-1 gene expression in MDD patients (Alcocer-Gómez and Cordero, 2013). In addition, glyburide, an anti-diabetic drug that inhibits caspase-1 activation and IL-1β secretion, may also serve as an effective inhibitor of NLRP3 formation following stress-induced depression (Lamkanfi et al., 2009). Furthermore, Warner-Schmidt and colleagues found an antagonistic relationship between antidepressant drugs and anti-inflammatory agents in patients with depression (Warner-Schmidt et al., 2011). Of note, selective serotonin reuptake inhibitors (SSRIs), but not tricyclic antidepressants, increased TNF-α and IFN-γ levels in the frontal cortex, which was inhibited by anti-inflammatory agents (i.e., NSAIDs) (Warner-Schmidt et al., 2011). This finding suggests that SSRIs and tricyclic antidepressants depend on different mechanisms to interact with anti-inflammatory drugs. Therefore, future clinical trials should consider the different effects of anti-inflammatory drugs on the efficacy of antidepressant agents in patients suffering from depression (Warner-Schmidt et al., 2011).

Depression-induced NLRP3 activation has been shown to correlate with many comorbid systemic illnesses (i.e., diabetes, cancer, and cardiovascular disease) (Iwata et al., 2013; Menu and Vince, 2011). Since cytokine secretion and inflammasome formation respond to stimuli other than invasive pathogens (i.e. psychological stressors), the inflammasome may transcend such psychological stimuli into an inflammatory response. In an evolutionary sense, the inflammasome may have adapted its pathway over time to include psychological stress due to the social interaction and non-pathogenic danger signals from the environment (Raison and Miller, 2013). Considering the prevalence and potential consequences of major depressive disorder, future research should continue to focus on the role of inflammasome activation in this disease.

CONCLUSION

Inflammasomes are multi-protein complexes involved in the immune system and inflammation. In this review, we have elaborated on the involvement of the NLRP3 inflammasome in various metabolic and cognitive diseases, including obesity, type 2 diabetes mellitus, Alzheimer’s disease, and major depressive disorder. In addition, other neurodegenerative diseases, such as Parkinson’s disease (Lu et al., 2014; Wang et al., 2014b) and Huntington’s disease (Glykys, 2008), have been associated with the NLRP3 inflammasome. While this review focused on NLRP3, other inflammasomes, such as those belonging to the NLR family and the AIM2 inflammasome, may provide a foundation for future research. Due to potential pleiotropic effects of inflammasome formation and their associated cytokines in various disease models, further elucidation of their regulation and functional significance is warranted. Novel therapeutic strategies for modulation of inflammasome activation should continue to be developed for possible clinical application in the near future.

REFERENCES


